GNRO — Geneuro SA Share News
0.000.00%
Last trade - 00:00HealthcareHighly SpeculativeMicro Cap
Brief: GeNeuro Says Company's Operations Funded Until Q2-2023
Brief: Geneuro/Fondamental Foundation: Early Results For Treatment Of Patients With Post-Covid Neuropsychiatric Syndromes
Brief: GeNeuro FY Operating Loss Narrows To 6.4 Million Euros
Brief: Geneuro: Protect-MS Phase 2 Trial Confirms Safety Of Higher Doses Of Temelimab In Multiple Sclerosis
Brief: Geneuro End-Dec Net Cash Position Of Eur 5.5 Mln, Financial Visibility To Q1 2023
Brief: Geneuro Receives EUR 6.4 Million In Funding From Swiss Government For Development Of Temelimab Against Long-Covid
Brief: GeNeuro Says Novel Pre-Clinical Results Confirm Potential Of Its Novel Anti-HERV-K Antibody For Amyotrophic Lateral Sclerosis
Brief: GeNeuro H1 Operating Loss Narrows To 3.5 Million Euros
Brief: GeNeuro Partners With Northwestern University Enter On Research On HERV-W ENV In Long-Haul COVID
Brief: Geneuro: 1st Patient Having Finished Protect-MS Study Has Entered Study Extension
Brief: Geneuro Says A First Patient Has Entered The ProTEct-MS Study Extension
Brief: Geneuro Reports End-Q2 Net Cash Position Of 9.2 Million Euros
Brief: GeNeuro Announces Results From CHANGE-MS and ANGEL-MS Studies
Brief: GeNeuro Announces Successful Private Placement of Eur 6 Mln
Brief: GeNeuro Launches EUR 6.5 Mln Private Placement
Brief: GeNeuro And Ciri Expand Focus To Post-COVID Syndromes
Brief: Geneuro Researchers Detect HERV-W ENV IN Covid-19 Patients
Brief: GeNeuro Q1 Net Cash Position Of 4.8 Million Euros
Brief: GeNeuro FY Operating Loss Narrows To 7.5 Million Euros